EMD Stock Overview
A clinical-stage biotech company, engages in the development of treatments for unmet medical needs.
Snowflake Score | |
---|---|
Valuation | 0/6 |
Future Growth | 0/6 |
Past Performance | 0/6 |
Financial Health | 4/6 |
Dividends | 0/6 |
Emyria Limited Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | AU$0.048 |
52 Week High | AU$0.13 |
52 Week Low | AU$0.04 |
Beta | 0.86 |
11 Month Change | 4.35% |
3 Month Change | -18.64% |
1 Year Change | -60.00% |
33 Year Change | -74.05% |
5 Year Change | n/a |
Change since IPO | -66.90% |
Recent News & Updates
Recent updates
Will Emyria (ASX:EMD) Spend Its Cash Wisely?
Feb 02We're Hopeful That Emyria (ASX:EMD) Will Use Its Cash Wisely
May 20Here's Why We're Not Too Worried About Emyria's (ASX:EMD) Cash Burn Situation
Oct 20We Think Emyria (ASX:EMD) Needs To Drive Business Growth Carefully
Jun 11Will Emyria (ASX:EMD) Spend Its Cash Wisely?
Feb 25Need To Know: Emyria Limited (ASX:EMD) Insiders Have Been Buying Shares
Nov 17Shareholder Returns
EMD | AU Pharmaceuticals | AU Market | |
---|---|---|---|
7D | -15.8% | 8.0% | 3.1% |
1Y | -60.0% | 62.2% | 10.0% |
Return vs Industry: EMD underperformed the Australian Pharmaceuticals industry which returned 61.2% over the past year.
Return vs Market: EMD underperformed the Australian Market which returned 9.2% over the past year.
Price Volatility
EMD volatility | |
---|---|
EMD Average Weekly Movement | 10.1% |
Pharmaceuticals Industry Average Movement | 10.2% |
Market Average Movement | 8.5% |
10% most volatile stocks in AU Market | 17.0% |
10% least volatile stocks in AU Market | 3.3% |
Stable Share Price: EMD's share price has been volatile over the past 3 months.
Volatility Over Time: EMD's weekly volatility (10%) has been stable over the past year.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
2018 | n/a | Michael Winlo | emyria.com |
Emyria Limited, a clinical-stage biotech company, engages in the development of treatments for unmet medical needs. The company develops psychedelic-assisted therapy, as well as MDMA drug discovery program. Its drug development program includes EMD-RX5 for treatment of psychological distress and mild stress and anxiety.
Emyria Limited Fundamentals Summary
EMD fundamental statistics | |
---|---|
Market cap | AU$19.63m |
Earnings (TTM) | -AU$11.95m |
Revenue (TTM) | AU$1.95m |
10.1x
P/S Ratio-1.6x
P/E RatioIs EMD overvalued?
See Fair Value and valuation analysisEarnings & Revenue
EMD income statement (TTM) | |
---|---|
Revenue | AU$1.95m |
Cost of Revenue | AU$2.19m |
Gross Profit | -AU$242.81k |
Other Expenses | AU$11.71m |
Earnings | -AU$11.95m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
Earnings per share (EPS) | -0.029 |
Gross Margin | -12.45% |
Net Profit Margin | -612.98% |
Debt/Equity Ratio | 204.4% |
How did EMD perform over the long term?
See historical performance and comparison